Valuation: Organovo Holdings Inc

Market Cap 3.15M 2.8M 2.62M 2.38M 4.49M 303M 4.55M 31.64M 12.25M 154M 11.82M 11.56M 496M P/E 2025
-1.32x
P/E 2026 -0.27x
Enterprise Value -1.31M -1.16M -1.09M -992K -1.87M -126M -1.89M -13.17M -5.1M -64.27M -4.92M -4.81M -206M EV / Sales 2025
-43,384,333x
EV / Sales 2026 -5,569,580x
Free-Float
97.33%
Yield 2025 *
-
Yield 2026 -
Manager TitleAgeSince
Chief Executive Officer 55 2006-12-31
Director of Finance/CFO 56 2024-12-29
Chief Tech/Sci/R&D Officer - 2026-01-05
Director TitleAgeSince
Chairman 55 2006-12-31
Director/Board Member 61 2012-01-31
Director/Board Member 55 2020-09-14
Change 5-day change 1-year change 3-year change Capi.($)
+4.16%-0.36%+49.37%+94.17% 74.46B
-0.61%+0.81%+27.25%+80.21% 60.14B
-2.54%-1.65%+4.86%+33.32% 48.15B
-2.80%-4.81%+28.47%+35.03% 44.25B
+0.90%+3.72%+352.03%+692.13% 43.99B
-1.76%+0.06%+7.47%+101.79% 41.61B
+3.32%+3.49%+11.18%+51.23% 29.97B
+4.77%+6.16%+36.77%+22.78% 29.31B
-3.72%-9.62%-25.41%+333.01% 24.93B
Average +0.19%+1.97%+54.67%+160.41% 44.09B
Weighted average by Cap. +0.36%+1.83%+58.94%+151.66%

Financials

2025 2026
Net sales 0.14 0.13 0.12 0.11 0.21 13.86 0.21 1.45 0.56 7.06 0.54 0.53 22.68 0.13 0.12 0.11 0.1 0.19 12.61 0.19 1.32 0.51 6.42 0.49 0.48 20.63
Net income -2.49M -2.21M -2.07M -1.88M -3.55M -240M -3.59M -25M -9.68M -122M -9.34M -9.14M -392M -13.84M -12.3M -11.5M -10.48M -19.73M -1.33B -20M -139M -53.85M -679M -51.97M -50.85M -2.18B
Net Debt -10.24M -9.1M -8.51M -7.75M -14.59M -986M -14.8M -103M -39.84M -502M -38.45M -37.62M -1.61B -4.46M -3.96M -3.7M -3.38M -6.35M -429M -6.44M -44.81M -17.35M -219M -16.74M -16.38M -702M
Logo Organovo Holdings Inc
VivoSim Labs, Inc. is a pharmaceutical and biotechnology services company, which is focused on providing testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine. The Company offers partners liver and intestinal toxicology insights using its new approach methodologies (NAM) models. The Company offers liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development. It uses its proprietary technologies to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, function, and disease. The Company also advances product candidates to treat inflammatory bowel disease (IBD) discovered and developed using its complex human tissue intestinal models.
Employees
-